Adjuvanted seasonal influenza vaccine - Vaxine

Drug Profile

Adjuvanted seasonal influenza vaccine - Vaxine

Alternative Names: Adjuvanted influenza vaccine - Vaxine

Latest Information Update: 16 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vaxine
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Influenza virus infections

Most Recent Events

  • 16 Sep 2015 Vaxine completes a phase I/II trial for Influenza virus infections (Prevention, In elderly subjects and patients with chronic diseases) in Australia (ACTRN12608000364370)
  • 20 Apr 2010 Clinical development of the Adjuvanted seasonal influenza vaccine is ongoing
  • 30 Nov 2006 Vaxine is seeking development partners for its adjuvanted influenza vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top